Reading this on a mobile device? Try our optimized mobile version here:

January 22, 2013
Sign upForwardArchiveAdvertise
News for nuclear medicine and molecular imaging professionals
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at

  Top Story 
  • Dual-tracer PET/CT can ID those who need liver transplant
    PET/CT imaging using combined carbon-11 acetate and FDG performed better than contrast-enhanced CT in diagnosing hepatocellular carcinoma and staging tumors in liver transplant patients and in partial hepatectomy cases, according to a study in the Journal of Nuclear Medicine. The dual-tracer PET/CT method identified HCC lesions in 94% of liver transplant patients and in 96% of partial hepatectomy patients. In terms of tumor-nodal-metastasis staging, the dual method showed 91% accuracy for the liver transplant group and 90% for the partial hepatectomy group. Overall, the method demonstrated 97% sensitivity and 92% specificity for patient selection for liver transplantation. "The inclusion of dual-tracer PET/CT in pretransplant workup may warrant serious consideration" in improving the determination of patients who are the most in need of a liver transplant, the researchers said. (free registration) (1/18) LinkedInFacebookTwitterEmail this Story
Your initiatives. Our technology. Together, we can reduce radiation exposure.
Utilizing a fully shielded, mobile design, the MEDRAD™ Intego™ enables sites to infuse doses-on-demand from a multi-dose vial, providing clinicians with added protection and more accurate, repeatable, patient-specific dosing. Click here to learn more.
  Clinical News & Research 
  • Software facilitates smoother analysis of PET/MRI scans
    NIH researchers have created software that allows for automated lesion segmentation on PET/MRI scans. The software lets clinicians detect parameters of diseased and healthy tissue, researchers reported at a radiology meeting. Tests showed the software can distinguish between lesions as accurately as manual lesion delineation. Researchers said the software can also be applied on PET/CT scans. (free registration) (1/21) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • SHINE shares update on LEU-based method for Mo-99 production
    SHINE Medical Technologies said the Los Alamos National Laboratory had succeeded in producing and separating molybdenum-99 from uranium sulfate solution. SHINE said the development shows the low-enriched uranium-based method can be used to produce the isotope on a commercial scale. The company is looking to meet at least 50% of the U.S. demand for the isotope by 2016. Wisconsin State Journal (Madison) (1/18) LinkedInFacebookTwitterEmail this Story
  • Dilon reports positive findings for MBI
    Dilon Diagnostics is reporting positive results for molecular breast imaging from two studies. The first study showed MBI has a higher sensitivity in finding cancers compared with mammography and ultrasound. In the second study, MBI performed comparably with MRI in identifying cancers. (free registration) (1/18) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • Experts discuss areas for improvement in cardiac SPECT practice
    Myocardial perfusion SPECT has seen double-digit growth in the U.S. for the past 15 years in terms of procedure volume, but there is still a need to address certain limitations with cardiac SPECT to boost its clinical value, according to this article. Experts say reducing the method's acquisition time, increasing adoption of SPECT/CT and developing more SPECT-specific tracers are key to moving forward. Experts believe improving the modality's acquisition time would lead to advantages in terms of reimbursement, image quality and management of patients and health care staff. The increasing number of obese and aging patients needing cardiac SPECT imaging could be drivers of growth for the modality. (1/17) LinkedInFacebookTwitterEmail this Story
  International Developments 
  • Canadian foundation to advance personalized medicine program
    The Princess Margaret Cancer Foundation in Toronto has secured $50.3 million from private funding. The foundation will use the money to support the Princess Margaret Cancer Centre's Personalized Cancer Medicine Initiative, which will focus on genomics, molecular imaging and tumor biology research to advance personalized treatments. The initiative will seek to explore ways to identify tumors earlier, evaluate them more accurately and treat them with more targeted methods and medicines. GenomeWeb Daily News (free registration) (1/21) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  • 6 states consider bills regarding biosimilars
    Six states are weighing bills involving the interchangeability of biosimilars and brand-name biologics. In Virginia, a legislative panel endorsed a bill that would authorize pharmacists to dispense biosimilars that the FDA considers interchangeable, while a Pennsylvania lawmaker says rules on generics aren't applicable to biosimilars and new legislation is needed. In 2012, changes were proposed to Illinois' Pharmacy Practice Act, while Indiana, North Dakota and Texas also are considering bills. Blog (1/18) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  • Health care groups give $4.25M to community health centers
    A first round of grants totaling $4.25 million will be given by Partners HealthCare and Neighborhood Health Plan to all community health centers affiliated with the Massachusetts League of Community Health Centers. The organizations expect the CHCs to use the funds for health IT systems adoption, medical coding and meaningful use training, as well as performance improvement initiatives. Government Health IT online (1/21) LinkedInFacebookTwitterEmail this Story
  From SNMMI 
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

It ain't what they call you, it's what you answer to."
--W.C. Fields,
American comedian, actor and writer

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Account Director:   Meryl Harold   (202) 407-7828
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.®  Legal Information